Mankind Pharma Ltd (MANKIND) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: Not available

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↓

-0.31%

Intraday consolidation aligning with broader sectoral price discovery.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 9.5%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 13.1%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 09 Nov 2026

50-Day DMA ● Overlay

₹2,566.90

200-Day DMA ● Overlay

₹2,380.70

14-Day RSI ● Overlay

50.9 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹97,819 Cr

Large cap

Stock P/E (TTM) Valuation

45.8x

Price / EPS

Book Value (₹) Assets

₹395.0

P/B: 6.0x

ROE (%) Quality

13.1%

Net Profit / Equity

ROCE (%) Efficiency

13.5%

EBIT / Capital

Dividend Yield Yield

0.04%

Face Value: ₹10

Debt / Equity Solvency

0.39x

Manageable

EPS (TTM) Per Share

₹51.70

Trailing 12M

OPM (%) Spread

26.0%

EBITDA Margin

Free Cash Flow Cash

₹2,387 Cr

CFO - Capex

About Mankind Pharma Ltd

Mankind Pharma Ltd (MANKIND) is a leading Indian enterprise operating in the Healthcare & Pharma sector.

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 18.7% × Turnover: 0.85x × Leverage: 1.39x = ROE: 13.1%

✓ Company Strengths (Pros)

• Maintains healthy operating profit margins of ~26.0%.
• TickerPulse fundamental algorithm rates overall quality at 80/100.

⚠ Key Considerations & Risks (Cons)

• Stock is trading at a premium of 6.0x its book value.

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹14,738 Cr

Latest PAT

₹2,068 Cr

EPS (TTM)

₹51.70

OPM %

26.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹2,579 Cr	₹2,708 Cr	₹2,607 Cr	₹2,422 Cr	₹2,868 Cr	₹3,061 Cr	₹3,199 Cr	₹3,079 Cr	₹3,570 Cr	₹3,697 Cr	₹3,567 Cr	₹3,443 Cr	₹4,031 Cr
Operating Profit (EBITDA)	₹655.00 Cr	₹683.00 Cr	₹606.00 Cr	₹586.00 Cr	₹672.00 Cr	₹847.00 Cr	₹816.00 Cr	₹683.00 Cr	₹847.00 Cr	₹921.00 Cr	₹919.00 Cr	₹930.00 Cr	₹1,056 Cr
OPM %	25.0%	25.0%	23.0%	24.0%	23.0%	28.0%	26.0%	22.0%	24.0%	25.0%	26.0%	27.0%	26.0%
Interest Expense	₹6.00 Cr	₹9.00 Cr	₹9.00 Cr	₹9.00 Cr	₹11.00 Cr	₹7.00 Cr	₹221.00 Cr	₹191.00 Cr	₹171.00 Cr	₹170.00 Cr	₹157.00 Cr	₹142.00 Cr	₹110.00 Cr
Depreciation	₹87.00 Cr	₹96.00 Cr	₹110.00 Cr	₹100.00 Cr	₹103.00 Cr	₹100.00 Cr	₹187.00 Cr	₹231.00 Cr	₹219.00 Cr	₹222.00 Cr	₹223.00 Cr	₹223.00 Cr	₹226.00 Cr
Profit before Tax (PBT)	₹624.00 Cr	₹641.00 Cr	₹562.00 Cr	₹572.00 Cr	₹666.00 Cr	₹849.00 Cr	₹495.00 Cr	₹511.00 Cr	₹540.00 Cr	₹624.00 Cr	₹509.00 Cr	₹659.00 Cr	₹769.00 Cr
Net Profit (PAT)	₹494.00 Cr	₹511.00 Cr	₹460.00 Cr	₹477.00 Cr	₹543.00 Cr	₹659.00 Cr	₹385.00 Cr	₹425.00 Cr	₹445.00 Cr	₹520.00 Cr	₹414.00 Cr	₹559.00 Cr	₹574.00 Cr
EPS in ₹	₹12.15	₹12.51	₹11.33	₹11.76	₹13.39	₹16.31	₹9.22	₹10.20	₹10.62	₹12.39	₹9.90	₹13.43	₹13.75

Annual P&L (₹ Cr)	Mar 2015	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	₹3,334 Cr	₹5,865 Cr	₹6,214 Cr	₹7,782 Cr	₹8,749 Cr	₹10,260 Cr	₹12,207 Cr	₹14,278 Cr	₹14,738 Cr
Expenses	₹2,748 Cr	₹4,427 Cr	₹4,565 Cr	₹5,791 Cr	₹6,848 Cr	₹7,743 Cr	₹9,182 Cr	₹10,653 Cr	₹10,911 Cr
Operating Profit	₹586.00 Cr	₹1,438 Cr	₹1,649 Cr	₹1,991 Cr	₹1,902 Cr	₹2,517 Cr	₹3,026 Cr	₹3,625 Cr	₹3,827 Cr
OPM %	18%	25%	27%	26%	22%	25%	25%	25%	26%
Interest	₹2.00 Cr	₹23.00 Cr	₹21.00 Cr	₹60.00 Cr	₹46.00 Cr	₹34.00 Cr	₹432.00 Cr	₹644.00 Cr	₹579.00 Cr
Depreciation	₹39.00 Cr	₹99.00 Cr	₹119.00 Cr	₹167.00 Cr	₹326.00 Cr	₹378.00 Cr	₹621.00 Cr	₹886.00 Cr	₹893.00 Cr
Profit before Tax	₹621.00 Cr	₹1,438 Cr	₹1,692 Cr	₹1,975 Cr	₹1,671 Cr	₹2,399 Cr	₹2,521 Cr	₹2,333 Cr	₹2,562 Cr
Net Profit	₹445.00 Cr	₹1,056 Cr	₹1,293 Cr	₹1,453 Cr	₹1,310 Cr	₹1,942 Cr	₹2,011 Cr	₹1,938 Cr	₹2,068 Cr
EPS in Rs	219.33	25.72	31.59	35.78	32.00	47.75	48.26	46.34	49.47

Balance Sheet (₹ Cr)	Mar 2015	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	₹20.00 Cr	₹40.00 Cr	₹40.00 Cr	₹40.00 Cr	₹40.00 Cr	₹40.00 Cr	₹41.00 Cr	₹41.00 Cr
Reserves & Surplus	₹2,035 Cr	₹3,445 Cr	₹4,682 Cr	₹6,115 Cr	₹7,395 Cr	₹9,323 Cr	₹14,291 Cr	₹16,259 Cr
Borrowings (Debt)	₹0 Cr	₹131.00 Cr	₹241.00 Cr	₹873.00 Cr	₹170.00 Cr	₹207.00 Cr	₹8,511 Cr	₹6,312 Cr
Total Liabilities	₹3,022 Cr	₹5,065 Cr	₹6,360 Cr	₹9,108 Cr	₹9,686 Cr	₹11,883 Cr	₹27,652 Cr	₹27,755 Cr
Fixed Assets	₹316.00 Cr	₹1,600 Cr	₹1,664 Cr	₹3,588 Cr	₹4,251 Cr	₹4,545 Cr	₹19,005 Cr	₹18,620 Cr
Total Assets	₹3,022 Cr	₹5,065 Cr	₹6,360 Cr	₹9,108 Cr	₹9,686 Cr	₹11,883 Cr	₹27,652 Cr	₹27,755 Cr

Cash Flows (₹ Cr)	Mar 2015	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operations (CFO)	₹0 Cr	₹1,070 Cr	₹1,137 Cr	₹920.00 Cr	₹1,813 Cr	₹2,152 Cr	₹2,413 Cr	₹3,121 Cr
Cash from Investing (CFI)	₹0 Cr	-₹436.00 Cr	-₹1,222 Cr	-₹1,369 Cr	-₹1,052 Cr	-₹2,081 Cr	-₹12,624 Cr	-₹181.00 Cr
Cash from Financing (CFF)	₹0 Cr	-₹531.00 Cr	-₹8.00 Cr	₹605.00 Cr	-₹740.00 Cr	₹5.00 Cr	₹10,233 Cr	-₹2,953 Cr
Free Cash Flow (FCF)	₹0 Cr	₹853.00 Cr	₹826.00 Cr	-₹1,423 Cr	₹987.00 Cr	₹1,771 Cr	₹1,895 Cr	₹2,387 Cr

Efficiency Ratios	Mar 2015	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days (DSO)	22	33	19	18	24	30	46	44
Inventory Days	166	175	243	265	188	180	219	193
Cash Conversion Cycle (Days)	117	63	125	121	86	120	146	117
ROCE %	0%	0%	37%	32%	22%	26%	17%	14%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹789.60 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹2,660.00

DCF Fair Value

₹789.60

Graham Number

₹677.85

Margin of Safety

-72.2%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹789.60

Premium / Overvalued (Margin: -72.2%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹768	₹761	₹755	₹748
10%	₹783	₹776	₹769	₹762
12%	₹797	₹790	₹782	₹776
14%	₹811	₹804	₹796	₹789

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹790	Fairly Valued
Benjamin Graham Number	₹678	Market Priced
Historical Sector P/E	₹1,137	Premium
EV / EBITDA Multiplier	₹2,793	In-Line
Free Cash Flow Yield Model	₹2,607	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 8/9 (Strong Financial Health)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

8 / 9 Pass

Altman Z-Score

4.43 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Debt/Equity: 0.39x (Safe)

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Positive Operating & Free Cash Flow

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 26.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

72.63%

FIIs (Foreign)

9.45%

DIIs (Domestic)

15.39%

Government

0.15%

Public / Retail

2.53%

Swipe → to view historical quarters

Category	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
+ Promoters	76.50%	76.50%	74.88%	74.87%	74.87%	72.71%	72.70%	72.67%	72.67%	72.66%	72.66%	72.63%
+ FIIs (Foreign Portfolio)	4.18%	6.74%	9.87%	11.58%	12.37%	13.34%	12.92%	13.07%	12.83%	11.34%	10.24%	9.45%
+ DIIs (Mutual Funds / Insurance)	4.56%	9.78%	11.14%	9.94%	9.91%	11.05%	11.47%	11.50%	11.91%	13.26%	14.46%	15.39%
+ Public (Retail & HNIs)	14.76%	6.97%	4.10%	3.61%	2.86%	2.89%	2.89%	2.75%	2.57%	2.75%	2.63%	2.53%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Healthcare & Pharma.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

MANKIND Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

MANKIND Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

MANKIND Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹3,404.80

Accelerated market share capture in Healthcare & Pharma, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹2,979.20

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 46x P/E.

🐻 Bear Case (15%) -12.0%

₹2,340.80

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Healthcare & Pharma)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 20:22 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ Mankind Pharma Ltd (MANKIND)	Target Stock	₹2,660.00	-0.31%	45.8x	13.1%	13.5%	0.39	₹97,819 Cr
Sun Pharmaceutical Industries Ltd (SUNPHARMA)	Specialty Pharma & Generics	₹1,902.30	-0.12%	34.2x	16.0%	20.5%	0.06	₹4.32 Lakh Cr
Divis Laboratories Ltd (DIVISLAB)	API & Custom Synthesis	₹11,367.00	-1.72%	82.4x	16.5%	22.0%	0.00	₹2.46 Lakh Cr
Torrent Pharmaceuticals Ltd (TORNTPHARM)	Sector Peer	₹4,761.00	-0.40%	86.1x	27.6%	19.8%	1.69	₹1.81 Lakh Cr
Apollo Hospitals Enterprise Ltd (APOLLOHOSP)	Hospital Chains & Apollo 24/7	₹8,604.00	+0.64%	53.9x	21.2%	17.4%	0.90	₹1.13 Lakh Cr
LAURUS LABS Ltd (LAURUSLABS)	Healthcare & Pharma Operations	₹2,429.00	-1.02%	99.7x	18.3%	17.8%	0.48	₹1.09 Lakh Cr
Cipla Ltd (CIPLA)	Respiratory & Generic Medicine	₹1,419.90	+1.15%	30.2x	11.6%	15.5%	0.02	₹1.08 Lakh Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	20:22:37 IST	✓ Live Sync
Financial Statements (10Y)	Mankind Pharma Ltd Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	11 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	11 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	11 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

Mankind Pharma Ltd

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About Mankind Pharma Ltd

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Healthcare & Pharma)

Metric Explainer

Stock DNA Methodology

Document Title